Mayne Pharma Group (ASX:MYX) rejected Cosette Pharmaceuticals' Tuesday notice to terminate the scheme implementation deed (SID) for the proposed acquisition of the company, according to a Wednesday filing with the Australian bourse.
It rejected the notice as invalid as Cosette is not entitled to terminate the SID, the filing said.
The company attempted to engage in consultation with Cosette, but has not been able to reach an agreement for the scheme to proceed, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments